Gene therapy RGX-314 holds potential for diabetic macular edema treatment, says analyst

28 July 2022

USA-based AbbVie (NYSE: ABBV) and Regenxbio (Nasdaq: RGNX) recently presented data from a Phase II study of its lead diabetic retinopathy (DR) and neovascular age-related macular degeneration (nAMD) gene therapy candidate, RGX-314, at the American Society of Retinal Specialists (ASRS) annual meeting, which took place on July 13-16.

RGX-314 has the potential to address a key unmet need for drugs that reduce patient burden and compliance-related issues among diabetic macular edema (DME) patients, says data and analytics company GlobalData.

Currently, patients receiving anti-vascular endothelial growth factor (VEGF) therapy for DME are obliged to visit the hospital six to eight times a year on average. However, despite being an anti-VEGF therapy, similar to many other treatments for DME including the gold standard Bayer’s (BAYN: DE) Eylea (aflibercept), RGX-314 is unique among anti-VEGF treatments as it is a gene therapy, and therefore offered as a one-time treatment.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK